bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Data from Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy
Authors: Panditharatna Eshini , Kilburn Lindsay B. , Aboian Mariam S. , Kambhampati Madhuri , Gordish-Dressman Heather , Magge Suresh N. , Gupta Nalin , Myseros John S. , Hwang Eugene I. , Kline Cassie , Crawford John R. , Warren Katherine E. , Cha Soonmee , Liang Winnie S. , Berens Michael E. , Packer Roger J. , Resnick Adam C. , Prados Michael , Mueller Sabine , Nazarian Javad
Published: April 2023

Supplementary figures 1-4 and supplementary table 3. Supplementary figure 1. Genomic DNA validation of probes, assessing sensitivity, and specificity of ddPCR platform. Supplementary figure 2. Novel detection of histone 3 mutation in fluid present in a brainstem tumor cyst found in a DIPG patient at postmortem. Supplementary figure 3. Longitudinal changes in plasma ctDNA in association with MR imaging findings and clinical assessments. Supplementary figure 4. Biofluid ctDNA and tumor spread as assessed by MRI, genomic, and/or histological studies. Supplementary table 3. Mutations analyzed in the study by ddPCR with corresponding design of primers and probes.
Supplementary Data from TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
Authors: Biton Jérôme , Mansuet-Lupo Audrey , Pécuchet Nicolas , Alifano Marco , Ouakrim Hanane , Arrondeau Jennifer , Boudou-Rouquette Pascaline , Goldwasser François , Leroy Karen , Goc Jeremy , Wislez Marie , Germain Claire , Laurent-Puig Pierre , Dieu-Nosjean Marie-Caroline , Cremer Isabelle , Herbst Ronald , Blons Hélène , Damotte Diane
Published: April 2023

Figures S1-12 Tables S1-S4 Supplementary material Supplementary Table S1. Antibodies used in flow cytometry experiments. Supplementary Table S2. Baseline characteristics of the 221 patients with lung adenocarcinoma in each TIP. Supplementary Table S3. Univariate Cox proportional-hazard analyses for progression-free survival and overall survival according to the mutational status of tumors in nivolumab treated patients. Supplementary Table S4. Baseline characteristics of the 32 patients with advanced-stages lung adenocarcinoma treated by nivolumab according to the mutational status of their tumor. Supplementary Figure S1. Spearman-correlation matrix of immune cell densities. Supplementary Figure S2. Comparison of immune cell densities, overall survival, molecular alteration frequency, and PD-L1 expression by tumor cells, between patients from TIP-1a and 1b. Supplementary Figure S3. TP53, STK11 and EGFR mutations strongly impact lung adenocarcinoma immune profiles. Supplementary Figure S4. Patterns of TP53, EGFR and STK11 mutations in the three TIPs. Supplementary Figure S5. No impact of KRAS mutations on the immune composition of TP53-Mut/STK11-EGFR-WT tumors and of TP53-STK11-EGFR-WT tumors. Supplementary Figure S6. Flow cytometry gating strategy used to characterize CD8 T cells from freshly resected tumors of lung adenocarcinoma patients. Supplementary Figure S7. Effector functions of CD8 TILs in TP53-Mut/STK11-EGFR-WT tumors vs TP53-WT tumors. Supplementary Figure S8. Higher MHC-I expression by malignant cells in TP53-Mut/ STK11- EGFR-WT tumors and its impact on tumor immune profiles. Supplementary Figure S9. Impact on the survival of nivolumab treated patients of TP53, KRAS, STK11 and EGFR mutations. Supplementary Figure S10. Anti-PD-1 efficacy in advanced-stage NSCLC patients according to distinct combinations of TP53, EGFR and STK11 mutations. Supplementary Figure S11. Impact of KRAS mutations on anti-PD-1 efficacy in advanced-stage NSCLC patients with TP53-Mut/STK11-EGFR-WT, TP53-STK11-EGFR-WT and in STK11-Mut/TP53-EGFR-WT tumors. Supplementary Figure S12. Impact of PD-L1 expression on the PFS of patients treated by anti-PD-1 according to distinct combinations of TP53, EGFR and STK11 mutations.
Supplementary Table 4. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Authors: Gordevičius Juozas , Kriščiūnas Algimantas , Groot Daniel E. , Yip Steven M. , Susic Miki , Kwan Andrew , Kustra Rafal , Joshua Anthony M. , Chi Kim N. , Petronis Art , Oh Gabriel
Published: April 2023

DAVID analysis of AA-DMPs at FDR q < 0.2 and AA-DVPs measured across patient groups for each visit.
Supplementary Data from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Authors: Gordevičius Juozas , Kriščiūnas Algimantas , Groot Daniel E. , Yip Steven M. , Susic Miki , Kwan Andrew , Kustra Rafal , Joshua Anthony M. , Chi Kim N. , Petronis Art , Oh Gabriel
Published: April 2023

Supplementary methods, supplementary table legends, and all supplementary figures.
Supplemental Document from Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival
Authors: Subbiah Vivek , Lamhamedi-Cherradi Salah-Eddine , Cuglievan Branko , Menegaz Brian A. , Camacho Pamela , Huh Winston , Ramamoorthy Vandhana , Anderson Pete M. , Pollock Raphael E. , Lev Dina C. , Qiao Wei , McAleer Mary Frances , Benjamin Robert S. , Patel Shreyaskumar , Herzog Cynthia E. , Daw Najat C. , Feig Barry W. , Lazar Alexander J. , Hayes-Jordan Andrea , Ludwig Joseph A.
Published: April 2023

Supplemental Figure Legends
Supplementary Figure S5 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Authors: Chen Justin , Haanpää Maria K. , Gruber Joshua J. , Jäger Natalie , Ford James M. , Snyder Michael P.
Published: April 2023

Figure S5. Seven additional samples with hypermethylation at the PTEN promoter also have bimodal density peaks (red) when compared to universally unmethylated reads in healthy controls (blue), but at methylated:unmethylated ratios that range from 0.18-0.53.
Supplementary Document from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Authors: Chen Justin , Haanpää Maria K. , Gruber Joshua J. , Jäger Natalie , Ford James M. , Snyder Michael P.
Published: April 2023

Supplemental Table S1, Figure S1, and Figure Legends for Figure S2 - S5 Table S1. Number of potential allelic methylation sites identified per sample Figure S1. Flow diagram summarizing the strategy for study cohort selection consisting of high-risk breast cancer family index patients.
Figure S1 from Effect of Perioperative Opioids on Cancer-Relevant Circulating Parameters: Mu Opioid Receptor and Toll-Like Receptor 4 Activation Potential, and Proteolytic Profile
Authors: Xie Nan , Matigian Nicholas , Vithanage Tharindu , Gregory Kye , Nassar Zeyad D. , Cabot Peter J. , Shaw Paul N. , Kirkpatrick Carl M.J. , Cao Kim-Anh Lê , Sturgess David , Parat Marie-Odile
Published: April 2023

Comparison of receptor activation potential between healthy subjects and preoperative patient samples. A) MOR activation was determined via HEK-MOP cAMP production by the AlphascreenTM assay using 5% (v/v) human plasma. B, C) HEK-Blue{trade mark, serif} hTLR4 cells were exposed to 5% (v/v) human plasma (B), or 5% (v/v) human plasma in the presence of 1 ng/mL LPS (C). SEAP activity was determined using QUANTI-Blue{trade mark, serif}. Data are shown as mean {plus minus} SEM, n=60 patients and 10 healthy participants, ****, p<0.0001, unpaired Student's t-test (Two-tailed).
Supplementary Figure legends (Figure S1-S7) from CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia
Authors: Ajiro Masahiko , Sakai Hiroyuki , Onogi Hiroshi , Yamamoto Makoto , Sumi Eriko , Sawada Teruo , Nomura Takashi , Kabashima Kenji , Hosoya Takamitsu , Hagiwara Masatoshi
Published: April 2023

Supplementary Figure legends (Figure S1-S7)
Table S1 from The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy
Authors: Yordanova Anna , Wicharz Marcel M. , Mayer Karin , Brossart Peter , Gonzalez-Carmona Maria A. , Strassburg Christian P. , Fimmers Rolf , Essler Markus , Ahmadzadehfar Hojjat
Published: April 2023

Subgroups: patients' characteristics.
Supplementary Table 1 from p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial
Authors: Sperinde Jeff , Huang Weidong , Vehtari Aki , Chenna Ahmed , Kellokumpu-Lehtinen Pirkko-Liisa , Winslow John , Bono Petri , Lie Yolanda S. , Petropoulos Christos J. , Weidler Jodi , Joensuu Heikki
Published: April 2023

Supplementary Table 1
Supplementary Figure S1 from p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial
Authors: Sperinde Jeff , Huang Weidong , Vehtari Aki , Chenna Ahmed , Kellokumpu-Lehtinen Pirkko-Liisa , Winslow John , Bono Petri , Lie Yolanda S. , Petropoulos Christos J. , Weidler Jodi , Joensuu Heikki
Published: April 2023

Supplementary Figure 1
Table S2 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration
Authors: Liu Qiuli , Tong Dali , Liu Gaolei , Gao Jie , Wang Lin-ang , Xu Jing , Yang Xingxia , Xie Qiubo , Huang Yiqiang , Pang Jian , Wang Luofu , He Yong , Zhang Dianzheng , Ma Qiang , Lan Weihua , Jiang Jun
Published: April 2023

Supplementary Table S2. The numbers of the lesions in each group at indicated time points.
Supplementary Data_clean from 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
Authors: Moek Kirsten L. , Waaijer Stijn J.H. , Kok Iris C. , Suurs Frans V. , Brouwers Adrienne H. , Menke-van der Houven van Oordt C. Willemien , Wind Thijs T. , Gietema Jourik A. , Schröder Carolien P. , Mahesh Shekar V.K. , Jorritsma-Smit Annelies , Lub-de Hooge Marjolijn N. , Fehrmann Rudolf S.N. , de Groot Derk Jan A. , de Vries Elisabeth G.E.
Published: April 2023

Supplementary methods, Supplementary Fig. S1, Supplemtary Table S1, Supplementary Table S2, Supplementary Table S3
Table S7 from A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Authors: Tamborero David , Rubio-Perez Carlota , Muiños Ferran , Sabarinathan Radhakrishnan , Piulats Josep M. , Muntasell Aura , Dienstmann Rodrigo , Lopez-Bigas Nuria , Gonzalez-Perez Abel
Published: April 2023

Results of the GSEA enrichment
Figure S6 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration
Authors: Liu Qiuli , Tong Dali , Liu Gaolei , Gao Jie , Wang Lin-ang , Xu Jing , Yang Xingxia , Xie Qiubo , Huang Yiqiang , Pang Jian , Wang Luofu , He Yong , Zhang Dianzheng , Ma Qiang , Lan Weihua , Jiang Jun
Published: April 2023

Supplementary Figure S6. The direct effects of metformin on macrophage RAW264.7 cells. (A and B) RAW264.7 cells were seeded in 6-well plates and treated with LPS (1 ug/ml) and different concentrations (0, 0.2, 1, 5, 25, 125 mM) of metformin for 48 h. The media were collected for ELISA assays of IL-6 and TNF-Î±.
Table S5 from A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Authors: Tamborero David , Rubio-Perez Carlota , Muiños Ferran , Sabarinathan Radhakrishnan , Piulats Josep M. , Muntasell Aura , Dienstmann Rodrigo , Lopez-Bigas Nuria , Gonzalez-Perez Abel
Published: April 2023

Enrichment for somatic driver alterations across tumor immune-phenotypes
Table S4 from A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Authors: Tamborero David , Rubio-Perez Carlota , Muiños Ferran , Sabarinathan Radhakrishnan , Piulats Josep M. , Muntasell Aura , Dienstmann Rodrigo , Lopez-Bigas Nuria , Gonzalez-Perez Abel
Published: April 2023

Immune-phenotypes
Table S2 from A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Authors: Tamborero David , Rubio-Perez Carlota , Muiños Ferran , Sabarinathan Radhakrishnan , Piulats Josep M. , Muntasell Aura , Dienstmann Rodrigo , Lopez-Bigas Nuria , Gonzalez-Perez Abel
Published: April 2023

Details of the meta-processes employed (in Figure 4) in the description of tumor development in the three scenarios of immune infiltration
Supplementary Figure S3 from Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma
Authors: Cai Zhixiong , Chen Geng , Zeng Yongyi , Dong Xiuqing , Li Zhenli , Huang Yanbing , Xin Fuli , Qiu Liman , Xu Haipo , Zhang Wei , Su Xiaoping , Liu Xiaolong , Liu Jingfeng
Published: April 2023

Figure S3. CNVs levels between preoperative plasma samples and matched tumor in enrolled patients. The genome-wide copy number plots showed the correlation of CNVs between preoperative plasma and matched tumor. The calculated CNV fractions were also provided. Only patients with CNV fraction>0 in preoperative plasma sample were shown.
Supplementary Figure S4 from SS18-SSX–Dependent YAP/TAZ Signaling in Synovial Sarcoma
Authors: Isfort Ilka , Cyra Magdalene , Elges Sandra , Kailayangiri Sareetha , Altvater Bianca , Rossig Claudia , Steinestel Konrad , Grünewald Inga , Huss Sebastian , Eßeling Eva , Mikesch Jan-Henrik , Hafner Susanne , Simmet Thomas , Wozniak Agnieszka , Schöffski Patrick , Larsson Olle , Wardelmann Eva , Trautmann Marcel , Hartmann Wolfgang
Published: April 2023

Treatments with mono verteporfin and the combination of verteporfin and doxorubicin resulted in a reduction of YAP, TAZ, FOXM1, CTGF and PLK1 protein levels compared to the vehicle control and mono doxorubicin treatment in total protein extracts of a representative set of SySa PDX mice tumors (GAPDH used as loading reference).
Supplementary Data from The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo
Authors: Zhang Yu , Zhou Liang , Bandyopadhyay Dipankar , Sharma Kanika , Allen Alexander Joseph , Kmieciak Maciej , Grant Steven
Published: April 2023

Supplementary Data
Table S9 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S9
Table S6 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S6
Table S2 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S2
Supplementary Tables from Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma
Authors: Idbaih Ahmed , Canney Michael , Belin Lisa , Desseaux Carole , Vignot Alexandre , Bouchoux Guillaume , Asquier Nicolas , Law-Ye Bruno , Leclercq Delphine , Bissery Anne , De Rycke Yann , Trosch Clementine , Capelle Laurent , Sanson Marc , Hoang-Xuan Khe , Dehais Caroline , Houillier Caroline , Laigle-Donadey Florence , Mathon Bertrand , André Arthur , Lafon Cyril , Chapelon Jean-Yves , Delattre Jean-Yves , Carpentier Alexandre
Published: April 2023

Supplementary Table 1. The acoustic pressure levels are determined by a calibration of the implants in water prior to implantation in patients. The 95% confidence interval given in the table denotes the measurement uncertainty inherent to this process. Acoustic pressure levels reported previously (19) were re-evaluated using enhanced acoustic calibration methods with reduced uncertainty. The former values are given in the pold column to ease comparison with our previous publication. Supplementary Table 2. BBB disruption grade and acoustic pressure. Data are n (%). Supplementary Table 3. The secondary outcomes of the trial were calculated based on the grading assigned to post-contrast MR images evaluating the level of BBB disruption. Greater amounts of post-sonication BBB disruption resulted in a trend towards longer PFS and OS.
Figure S1 from First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Authors: Tao Jessica J. , Cangemi Nicholas A. , Makker Vicky , Cadoo Karen A. , Liu Joyce F. , Rasco Drew W. , Navarro Willis H. , Haqq Christopher M. , Hyman David M.
Published: April 2023

Resolution of hepatic steatosis liver in a patient with ovarian granulosa cell tumor following 2 months of treatment with STM 434 (0.75 mg/kg Q2W dose). An increase in 40 Hounsfield units is reflected after 2 months of therapy.
Supplementary Data from Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
Authors: Filipits Martin , Dubsky Peter , Rudas Margaretha , Greil Richard , Balic Marija , Bago-Horvath Zsuzsanna , Singer Christian F. , Hlauschek Dominik , Brown Krystal , Bernhisel Ryan , Kronenwett Ralf , Lancaster Johnathan M. , Fitzal Florian , Gnant Michael
Published: April 2023

Supplementary Tables S1-S7 & Figure S1
Supplementary Data Table 1 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Authors: Wang Victoria E. , Xue Jenny Y. , Frederick Dennie T. , Cao Yi , Lin Eva , Wilson Catherine , Urisman Anatoly , Carbone David P. , Flaherty Keith T. , Bernards Rene , Lito Piro , Settleman Jeff , McCormick Frank
Published: April 2023

Table S1 shows mutations in A375 VemR cells compared to the parental using exome sequencing.
Supplementary Data - text from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Data - text
Supplementary Data from Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors
Authors: Cooper Jonathan M. , Patel Amish J. , Chen Zhiguo , Liao Chung-Ping , Chen Kun , Mo Juan , Wang Yong , Le Lu Q.
Published: April 2023

Figure S1 shows the sequencing results for CRISPR/Cas9 gene editing to delete Brd4 in mouse MPNST cells; Figure S2 shows that BRD4 depletion overcomes resistance to BET inhibitor-induced cell death in MPNST; Figure S3 shows that genetic inhibition of BRD3 is sufficient to enhance MPNST cell sensitivity to JQ1; Figure S4 shows that JQ1 co-treatment with ARV771 does not markedly augment the apoptosis-initiation efficacy of ARV771 alone; Figure S5 shows that BET PROTAC ARV771 displays therapeutic efficacy in a human tumorigenic MPNST xenograft model.
Supplementary Figure 5 and 6 from Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer–A Perspective on Future Trial Designs
Authors: Ventz Steffen , Trippa Lorenzo , Schoenfeld Jonathan D.
Published: April 2023

Figure S5: Operating characteristics, efficacy scenario 2 (an average of 4.8, 3.6 and 2.4 AEs per patients under toxicity scenarios 1, 2, 3) for DeEscalate. Figure S6: Operating characteristics, efficacy scenario 2 (an average of 4.8, 3.6 and 2.4 AEs per patients under toxicity scenarios 1, 2, 3) for DeEscalate.
Supplementary Tables from Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations
Authors: Suehara Yoshiyuki , Alex Deepu , Bowman Anita , Middha Sumit , Zehir Ahmet , Chakravarty Debyani , Wang Lu , Jour George , Nafa Khedoudja , Hayashi Takuo , Jungbluth Achim A. , Frosina Denise , Slotkin Emily , Shukla Neerav , Meyers Paul , Healey John H. , Hameed Meera , Ladanyi Marc
Published: April 2023

Supplementary Tables S1-S8
Supplementary Figure 1 and 2 from Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer–A Perspective on Future Trial Designs
Authors: Ventz Steffen , Trippa Lorenzo , Schoenfeld Jonathan D.
Published: April 2023

Figure S1: Operating characteristics, efficacy scenario 1 (an average of 3.2, 2.4 and 1.6 AEs per patients under toxicity scenarios 1, 2, 3) for RTOG 1016. Figure S2: Operating characteristics, efficacy scenario 2 (an average of 3.2, 2.4 and 1.6 AEs per patients under toxicity scenarios 1, 2, 3) for RTOG 1016.
Supplementary Table 1 from Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Authors: Blagden Sarah P. , Hamilton Anne L. , Mileshkin Linda , Wong Shirley , Michael Agnieszka , Hall Marcia , Goh Jeffrey C. , Lisyanskaya Alla S. , DeSilvio Michelle , Frangou Eleni , Stronach Euan A. , Gopalakrishna Prashanth , Meniawy Tarek M. , Gabra Hani
Published: April 2023

Summary of exposure to afuresertib, paclitaxel and carboplatin
Supplementary Data from Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
Authors: Takenaka Masataka , Köbel Martin , Garsed Dale W. , Fereday Sian , Pandey Ahwan , Etemadmoghadam Dariush , Hendley Joy , Kawabata Ayako , Noguchi Daito , Yanaihara Nozomu , Takahashi Hiroyuki , Kiyokawa Takako , Ikegami Masahiro , Takano Hirokuni , Isonishi Seiji , Ochiai Kazuhiko , Traficante Nadia , Gadipally Sreeja , Semple Timothy , Vassiliadis Dane , Amarasinghe Kausyalya , Li Jason , Mir Arnau Gisela , Okamoto Aikou , Friedlander Michael , Bowtell David D. L.
Published: April 2023

Supplementary Tables
Supplementary Data from Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery
Authors: Hernandez Vargas Servando , Kossatz Susanne , Voss Julie , Ghosh Sukhen C. , Tran Cao Hop S. , Simien Jo , Reiner Thomas , Dhingra Sadhna , Fisher William E. , Azhdarinia Ali
Published: April 2023

Supplementary figures and tables. "Clean" version.
Supplementary table from Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array
Authors: Li Jiuyi , Xue Yang , Wenger Anna , Sun Yingyu , Wang Zheng , Zhang Chuanbao , Zhang Yunqiu , Fekete Boglarka , Rydenhag Bertil , Jakola Asgeir Store , Jiang Tao , Carén Helena , Fan Xiaolong
Published: April 2023

Supplementary table shows the information of samples invovled in this study and the information of TLDA assays.
Figure S2 from Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array
Authors: Li Jiuyi , Xue Yang , Wenger Anna , Sun Yingyu , Wang Zheng , Zhang Chuanbao , Zhang Yunqiu , Fekete Boglarka , Rydenhag Bertil , Jakola Asgeir Store , Jiang Tao , Carén Helena , Fan Xiaolong
Published: April 2023

Figure S2 shows high contamination of non-tumor tissues in glioma samples with the EMlowPMlow phenotype.
Supplementary Data from Radiomics on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma
Authors: Kim Sungwon , Shin Jaeseung , Kim Do-Young , Choi Gi Hong , Kim Myeong-Jin , Choi Jin-Young
Published: April 2023

Supplementary Data
Supplemental Table 3 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Authors: Chumsri Saranya , Serie Daniel J. , Li Zhuo , Pogue-Geile Katherine L. , Soyano-Muller Aixa E. , Mashadi-Hossein Afshin , Warren Sarah , Lou Yanyan , Colon-Otero Gerardo , Knutson Keith L. , Perez Edith A. , Moreno-Aspitia Alvaro , Thompson E. Aubrey
Published: April 2023

Supplemental Table 3
Supplemental Figure 2 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Authors: Chumsri Saranya , Serie Daniel J. , Li Zhuo , Pogue-Geile Katherine L. , Soyano-Muller Aixa E. , Mashadi-Hossein Afshin , Warren Sarah , Lou Yanyan , Colon-Otero Gerardo , Knutson Keith L. , Perez Edith A. , Moreno-Aspitia Alvaro , Thompson E. Aubrey
Published: April 2023

Supplemental Figure 2
Supplemental Figure 1 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Authors: Chumsri Saranya , Serie Daniel J. , Li Zhuo , Pogue-Geile Katherine L. , Soyano-Muller Aixa E. , Mashadi-Hossein Afshin , Warren Sarah , Lou Yanyan , Colon-Otero Gerardo , Knutson Keith L. , Perez Edith A. , Moreno-Aspitia Alvaro , Thompson E. Aubrey
Published: April 2023

Supplemental Figure 1
Figure S3 from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Authors: Balakrishnan Ashwini , Rajan Anusha , Salter Alexander I. , Kosasih Paula L. , Wu Qian , Voutsinas Jenna , Jensen Michael C. , Plückthun Andreas , Riddell Stanley R.
Published: April 2023

FIGURE S3: Transduced targets for testing of multispecific CARs.
Table S2 from Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Authors: Kraya Adam A. , Maxwell Kara N. , Wubbenhorst Bradley , Wenz Brandon M. , Pluta John , Rech Andrew J. , Dorfman Liza M. , Lunceford Nicole , Barrett Amanda , Mitra Nandita , Morrissette Jennifer J.D. , Feldman Michael , Nayak Anupma , Domchek Susan M. , Vonderheide Robert H. , Nathanson Katherine L.
Published: April 2023

Characteristics of breast cancers ascertained from Penn Medicine hospitals
Table S4 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Okamoto Isamu , Sriuranpong Virote , Vansteenkiste Johan , Imamura Fumio , Lee Jong Seok , Pang Yong-Kek , Cobo Manuel , Kasahara Kazuo , Cheng Ying , Nogami Naoyuki , Cho Eun Kyung , Su Wu Chou , Zhang Guili , Huang Xiangning , Li-Sucholeiki Xiaocheng , Lentrichia Brian , Dearden Simon , Jenkins Suzanne , Saggese Matilde , Rukazenkov Yuri , Ramalingam Suresh S.
Published: April 2023

Table S4 shows a comparison of central cobas tissue and baseline cobas plasma test results for EGFR-TKI sensitizing mutations (All screened patients)
Supp Figure 1 from Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation
Authors: Davidson Tom B. , Lee Alexander , Hsu Melody , Sedighim Shaina , Orpilla Joey , Treger Janet , Mastall Max , Roesch Saskia , Rapp Carmen , Galvez Mildred , Mochizuki Aaron , Antonios Joseph , Garcia Alejandro , Kotecha Nikesh , Bayless Nicholas , Nathanson David , Wang Anthony , Everson Richard , Yong William H. , Cloughesy Timothy F. , Liau Linda M. , Herold-Mende Christel , Prins Robert M.
Published: April 2023

Supplementary Figure 1: T cells from GBM patient TILs show highest expression of PD-1 compared to healthy donor PBMC and GBM patient PBMCs A) A representative flow cytometry plot measuring PD-1+ expression on CD4+ and CD8+ T cells from Healthy Donor PBMC, glioma Patient PBMC, and glioma patient TILs. B) Percent of PD-1 expression on CD4+ T cells from all the patient samples as measured by flow cytometry. C) Percent of PD-1 expression on CD8+ T cell from all the patient samples as measured by flow cytometry.
Table S1 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Okamoto Isamu , Sriuranpong Virote , Vansteenkiste Johan , Imamura Fumio , Lee Jong Seok , Pang Yong-Kek , Cobo Manuel , Kasahara Kazuo , Cheng Ying , Nogami Naoyuki , Cho Eun Kyung , Su Wu Chou , Zhang Guili , Huang Xiangning , Li-Sucholeiki Xiaocheng , Lentrichia Brian , Dearden Simon , Jenkins Suzanne , Saggese Matilde , Rukazenkov Yuri , Ramalingam Suresh S.
Published: April 2023

Table S1 gives a summary of all screened patients with uncommon EGFR mutations detected by the central cobas® EGFR Mutation Test
Supplementary Table S3 from Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Authors: Okada Morihito , Kijima Takashi , Aoe Keisuke , Kato Terufumi , Fujimoto Nobukazu , Nakagawa Kazuhiko , Takeda Yuichiro , Hida Toyoaki , Kanai Kuninobu , Imamura Fumio , Oizumi Satoshi , Takahashi Toshiaki , Takenoyama Mitsuhiro , Tanaka Hiroshi , Hirano Jun , Namba Yoshinobu , Ohe Yuichiro
Published: April 2023

Tumor response assessment by PD-L1 expression
Supplementary Data from Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Authors: Greally Megan , Chou Joanne F. , Chatila Walid K. , Margolis Matthew , Capanu Marinela , Hechtman Jaclyn F. , Tuvy Yaelle , Kundra Ritika , Daian Foysal , Ladanyi Marc , Kelsen David P. , Ilson David H. , Berger Michael F. , Tang Laura H. , Solit David B. , Diaz Luis A. , Schultz Nikolaus , Janjigian Yelena Y. , Ku Geoffrey Y.
Published: April 2023

Oncoprint
Supplementary Figure S1 from Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Authors: Okada Morihito , Kijima Takashi , Aoe Keisuke , Kato Terufumi , Fujimoto Nobukazu , Nakagawa Kazuhiko , Takeda Yuichiro , Hida Toyoaki , Kanai Kuninobu , Imamura Fumio , Oizumi Satoshi , Takahashi Toshiaki , Takenoyama Mitsuhiro , Tanaka Hiroshi , Hirano Jun , Namba Yoshinobu , Ohe Yuichiro
Published: April 2023

Kaplan-Meier curves for overall survival (A) and progressionfree survival (B) for all patients according tumor type (epithelioid and non-epithelioid subtypes)
Figure S4 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Authors: Ivanova Elena , Kuraguchi Mari , Xu Man , Portell Andrew J. , Taus Luke , Diala Irmina , Lalani Alshad S. , Choi Jihyun , Chambers Emily S. , Li Shuai , Liu Shengwu , Chen Ting , Barbie Thanh U. , Oxnard Geoffrey R. , Haworth Jacob J. , Wong Kwok-Kin , Dahlberg Suzanne E. , Aref Amir A. , Barbie David A. , Bahcall Magda , Paweletz Cloud P. , Jänne Pasi A.
Published: April 2023

Supplemental Figure 4. Change in body weight over time in HER2 YVMA GEMs treated with neratinib alone or in combination with trastuzumab.
Supplementary tables from Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer
Authors: Corredor Germán , Wang Xiangxue , Zhou Yu , Lu Cheng , Fu Pingfu , Syrigos Konstantinos , Rimm David L. , Yang Michael , Romero Eduardo , Schalper Kurt A. , Velcheti Vamsidhar , Madabhushi Anant
Published: April 2023

Table S1. List of all SpaTIL features. Table S2. List of the most discriminating spaTIL features for predicting recurrence in NSCLC. In this study, density is defined as the ratio of the number of cells within the cluster to the cluster pixel area, betweenness centrality is a measure of centrality in a graph based on shortest paths, and closeness centrality is a measure of centrality calculated as the sum of the length of the shortest paths between the node and all other nodes in the graph. Table S3: Summary of clinical and pathological features of the studied NSCLC cohorts. Table S4: Multivariable survival analysis on the test sets including SpaTIL. Table S5. Treatment information for the datasets included in this study.
Figure S1 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Authors: Ivanova Elena , Kuraguchi Mari , Xu Man , Portell Andrew J. , Taus Luke , Diala Irmina , Lalani Alshad S. , Choi Jihyun , Chambers Emily S. , Li Shuai , Liu Shengwu , Chen Ting , Barbie Thanh U. , Oxnard Geoffrey R. , Haworth Jacob J. , Wong Kwok-Kin , Dahlberg Suzanne E. , Aref Amir A. , Barbie David A. , Bahcall Magda , Paweletz Cloud P. , Jänne Pasi A.
Published: April 2023

Supplemental Figure 1. Characterization of DFCI 359 and DFCI 315.
Supplementary Tables from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Authors: Allen Bryan G. , Bodeker Kellie L. , Smith Mark C. , Monga Varun , Sandhu Sonia , Hohl Raymond , Carlisle Thomas , Brown Heather , Hollenbeck Nancy , Vollstedt Sandy , Greenlee Jeremy D. , Howard Matthew A. , Mapuskar Kranti A. , Seyedin Steven N. , Caster Joseph M. , Jones Karra A. , Cullen Joseph J. , Berg Daniel , Wagner Brett A. , Buettner Garry R. , TenNapel Mindi J. , Smith Brian J. , Spitz Douglas R. , Buatti John M.
Published: April 2023

Supplementary Table 1. Description of radiation treatment volumes (GTV, CTV, and PTV) Supplementary Table 2. Description of dose to organs at risk and treatment interruptions Supplemental Table 3. Subject count for key steps within the RT-phase of the clinical trial Supplemental Table 4. Subject count for key steps within the ADJ-phase of the clinical trial
Table S2 from Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
Authors: Dihge Looket , Vallon-Christersson Johan , Hegardt Cecilia , Saal Lao H. , Häkkinen Jari , Larsson Christer , Ehinger Anna , Loman Niklas , Malmberg Martin , Bendahl Pär-Ola , Borg Åke , Staaf Johan , Rydén Lisa
Published: April 2023

Nodal status across AIMS-PAM50 molecular subtypes within the development and validation cohorts
Figure S3 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S3
Supplementary Legend from Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma
Authors: Namikawa Kenjiro , Aung Phyu P. , Milton Denái R. , Tetzlaff Michael T. , Torres-Cabala Carlos A. , Curry Jonathan L. , Nagarajan Priyadharsini , Ivan Doina , Ross Merrick , Gershenwald Jeffrey E. , Prieto Victor G.
Published: April 2023

Supplementary Legend
Supplementary Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma
Authors: Thakur Rohit , Laye Jonathan P. , Lauss Martin , Diaz Joey Mark S. , O'Shea Sally Jane , Poźniak Joanna , Filia Anastasia , Harland Mark , Gascoyne Joanne , Randerson-Moor Juliette A. , Chan May , Mell Tracey , Jönsson Göran , Bishop D. Timothy , Newton-Bishop Julia , Barrett Jennifer H. , Nsengimana Jérémie
Published: April 2023

Supplementary Figures and tables
Supplementary Data from Targeting Glutamine Metabolism and Redox State for Leukemia Therapy
Authors: Gregory Mark A. , Nemkov Travis , Park Hae J. , Zaberezhnyy Vadym , Gehrke Sarah , Adane Biniam , Jordan Craig T. , Hansen Kirk C. , D’Alessandro Angelo , DeGregori James
Published: April 2023

Supplemental Materials and Methods
Supplementary Data from Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV− and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy
Authors: Xiao Roy , An Yi , Ye Wenda , Derakhshan Adeeb , Cheng Hui , Yang Xinping , Allen Clint , Chen Zhong , Schmitt Nicole C. , Van Waes Carter
Published: April 2023

Tables S1-3 and Figures S1-S8
Video from A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues
Authors: Natarajan Arutselvan , Patel Chirag B. , Ramakrishnan Sindhuja , Panesar Paramjyot S. , Long Steven R. , Gambhir Sanjiv S.
Published: April 2023

PET/CT video
Supplementary Data from Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer
Authors: Mell Loren K. , Shen Hanjie , Nguyen-Tân Phuc Felix , Rosenthal David I. , Zakeri Kaveh , Vitzthum Lucas K. , Frank Steven J. , Schiff Peter B. , Trotti Andy M. , Bonner James A. , Jones Christopher U. , Yom Sue S. , Thorstad Wade L. , Wong Stuart J. , Shenouda George , Ridge John A. , Zhang Qiang E. , Le Quynh-Thu
Published: April 2023

Supplementary Data: Tables S1-S2; Figures S1-S4
Supplementary Data from Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
Authors: Sundaravel Sriram , Kuo Wen-Liang , Jeong Jong Jin , Choudhary Gaurav S. , Gordon-Mitchell Shanisha , Liu Hui , Bhagat Tushar D. , McGraw Kathy L. , Gurbuxani Sandeep , List Alan F. , Verma Amit , Wickrema Amittha
Published: April 2023

Supplemental figure 5: A) Primary HSCs were treated with increasing doses of SHP-1 inhibitor, TPI-1 for 48 hours and viability was analyzed by staining with acridine orange-propidium iodide (AO-PI dye) using Nexcelom automated cell counter. Data are mean {plus minus}SEM from four biological replicates. Methylcellulose colony assays were setup using 1500 HSCs from healthy donors in the presence/absence of SHP-1 inhibitor, TPI-1 (4μM). After 14-16 days under differentiation conditions, B) Number of colonies formed were scored. Data are mean {plus minus}SEM from three biological replicates. C) Frequencies of colonies of different lineages were scored. Data are mean {plus minus}SEM from three biological replicates. D) ELISA was performed to determine beta hemoglobin expression. Data are represented as mean {plus minus}SEM from three technical replicates. E) Colony morphologies were analyzed after 14-16 days in methylcellulose (Scale bar, 100μM).
Supplementary Data from Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
Authors: Sundaravel Sriram , Kuo Wen-Liang , Jeong Jong Jin , Choudhary Gaurav S. , Gordon-Mitchell Shanisha , Liu Hui , Bhagat Tushar D. , McGraw Kathy L. , Gurbuxani Sandeep , List Alan F. , Verma Amit , Wickrema Amittha
Published: April 2023

Supplemental figure 6: A) Peripheral blood mononucleated cells were isolated from healthy, non- -7/(del)7q and -7/(del)7q MDS patient peripheral blood samples and flow cytometry analysis was performed to determine the percentages of CD34+ cells in these samples. Representative flow plot from one individual from each category is depicted. B) Quantitation of CD34+ cells from healthy (N=10), non- -7/(del)7q (N=13) and -7/(del)7q (N=6) MDS peripheral blood mononuclear cells (*P < 0.05; Student's t test.).
Supplementary Table S8 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S8
Supplementary Table S7 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S7
Supplementary Table S5 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S5
Table S1 from NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer
Authors: Gambardella Valentina , Gimeno-Valiente Francisco , Tarazona Noelia , Ciarpaglini Carolina Martinez , Roda Desamparados , Fleitas Tania , Tolosa Pablo , Cejalvo Juan Miguel , Huerta Marisol , Roselló Susana , Castillo Josefa , Cervantes Andrés
Published: April 2023

Primary antibodies used in this study.
Suppl. Fig. 7 from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

Individual tumor growth curves and tumor volumes for triple-treated mice with and without CXCR3 blockade.
Suppl. Fig. 2 from Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment
Authors: Luo Ren , Firat Elke , Gaedicke Simone , Guffart Elena , Watanabe Tsubasa , Niedermann Gabriele
Published: April 2023

Tumor growth delay analysis for the data presented in Fig. 1.
Table S1 from First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Authors: Vij Ravi , Nath Rajneesh , Afar Daniel E.H. , Mateos María-Victoria , Berdeja Jesús G. , Raab Marc S. , Guenther Andreas , Martínez-López Joaquín , Jakubowiak Andrzej J. , Leleu Xavier , Weisel Katja , Wong Shekman , Gulbranson Scott , Sheridan James P. , Reddy Anita , Paiva Bruno , Singhal Anil , San-Miguel Jesús F. , Moreau Philippe
Published: April 2023

Overall summary of treatment-emergent adverse events
Figure S2 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Authors: Baird Richard D. , van Rossum Annelot G.J. , Oliveira Mafalda , Beelen Karin , Gao Meiling , Schrier Mariette , Mandjes Ingrid A.M. , Garcia-Corbacho Javier , Vallier Anne-Laure , Dougall Greig , van Werkhoven Erik , Linossi Constanza , Kumar Sanjeev , van Tinteren Harm , Callari Maurizio , Beddowes Emma , Perez-Garcia José-Manuel , Rosing Hilde , Platte Else , Nederlof Petra , Schot Margaret , de Vries Schultink Aurelia , Bernards René , Saura Cristina , Gallagher William , Cortès Javier , Caldas Carlos , Linn Sabine C.
Published: April 2023

Pharmacokinetics: Z-endoxifen levels per taselisib dose level
Figure S1 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Authors: Baird Richard D. , van Rossum Annelot G.J. , Oliveira Mafalda , Beelen Karin , Gao Meiling , Schrier Mariette , Mandjes Ingrid A.M. , Garcia-Corbacho Javier , Vallier Anne-Laure , Dougall Greig , van Werkhoven Erik , Linossi Constanza , Kumar Sanjeev , van Tinteren Harm , Callari Maurizio , Beddowes Emma , Perez-Garcia José-Manuel , Rosing Hilde , Platte Else , Nederlof Petra , Schot Margaret , de Vries Schultink Aurelia , Bernards René , Saura Cristina , Gallagher William , Cortès Javier , Caldas Carlos , Linn Sabine C.
Published: April 2023

Taselisib pharmacokinetics in combination with tamoxifen
Supplementary Tables S1-3 from Genome-wide RNAi Screening Identifies RFC4 as a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair
Authors: Wang Xue-Cen , Yue Xin , Zhang Rong-Xin , Liu Ting-Yu , Pan Zhi-Zhong , Yang Meng-Jie , Lu Zhen-Hai , Wang Zi-Yang , Peng Jian-Hong , Le Li-Yuan , Wang Gao-Yuan , Peng Qi-Hua , Meng Yuan , Huang Wenlin , Liu Ran-Yi
Published: April 2023

Supplementary Table S1 shows the sequences of siRNAs; Supplementary Table S2 shows the informations of shRNAs; Supplementary Table S3 shows the sequences of quantitative PCR Primers.
Supplementary Table 1 from Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin
Authors: Lee Dae-Won , Han Sae-Won , Bae Jeong Mo , Jang Hoon , Han Hyojun , Kim Hyoki , Bang Duhee , Jeong Seung-Yong , Park Kyu Joo , Kang Gyeong Hoon , Kim Tae-You
Published: April 2023

Tumor mutation burden in MSI-H patients
Supplementary Data from Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy
Authors: Nie Yan , Huang Hongyan , Guo Mingyan , Chen Jiewen , Wu Wei , Li Wende , Xu Xiaoding , Lin Xiaorong , Fu Wenkui , Yao Yandan , Zheng Fang , Luo Man-Li , Saw Phei Er , Yao Herui , Song Erwei , Hu Hai
Published: April 2023

clean version
Supplementary Data from Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma
Authors: Thomas Reena P. , Nagpal Seema , Iv Michael , Soltys Scott G. , Bertrand Sophie , Pelpola Judith S. , Ball Robyn , Yang Jaden , Sundaram Vandana , Chernikova Sophia B. , Lavezo Jonathan , Born Donald , Vogel Hannes , Brown J. Martin , Recht Lawrence D.
Published: April 2023

Supplementary Data from Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma
Supplementary figures 1-8 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Figure S1. Additional analysis of siRNA effects on ciliation and target depleton. Supplementary Figure S2. Sorafenib is similar to sunitinib in inducing ciliary resorption. Supplementary Figure S3. Effect of compounds on AURKA catalytic activity. Supplementary Figure S4. Representative images demonstrating the effect of sunitinib (A) and ganetespib (B) on cilia resorption in hTERT-RPE1-Arl13b-GFP cells. Supplementary Figure S5. Cilia length upon treatment with indicated cilia-stabilizing compounds in hTERT-RPE1 (A) and NIH3T3 (B) cell lines. Supplementary Figure S6. Drug effects on ciliation correspond to changes in cell cycle over time. Supplementary Figure S7. Erlotinib increases ciliation in CFPAC-1 but not in PNX0010 cell line. Supplementary Figure S8. Representative Western blot images and quantitation of PDGF-AA-induced activation of PDGFR and MEK1/2 in NIH3T3 cells, related to Figures 3F, G.
Supplementary Figure 2B from A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer
Authors: Harding James J. , Zhu Andrew X. , Bauer Todd M. , Choueiri Toni K. , Drilon Alexander , Voss Martin H. , Fuchs Charles S. , Abou-Alfa Ghassan K. , Wijayawardana Sameera R. , Wang Xuejing Aimee , Moser Brian A. , Uruñuela Arantxa , Wacheck Volker , Bendell Johanna C.
Published: April 2023

Progression-free Survival in HCC population, MET +23